• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Pfizer-BioNTech Seek EUA for Omicron Booster in Children Aged Under 5 Years


Pfizer and BioNTech submitted an application to the US Food and Drug Administration (FDA) for emergency use authorization (EUA) of their omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the 3-dose primary series for children aged 6 months to 4 years.



On Monday, the companies announced that they are suggesting a primary series consisting of two 3-µg doses of their original COVID-19 vaccine, followed by a third, 3-µg dose of the omicron BA.4/BA.5-adapted bivalent vaccine.

“With the high level of respiratory illnesses currently circulating among children under 5 years of age, updated COVID-19 vaccines may help prevent severe illness and hospitalization,” said the companies in the December 5, 2022, statement.

In mid-October, the FDA amended the EUAs of the Moderna and Pfizer-BioNTech COVID-19 bivalent booster shots for use in older children and teenagers. Both company’s bivalent boosters can now be administered at least 2 months after primary or booster vaccination, the Moderna shot in children aged 6 to 17 years and the Pfizer counterpart in those aged 5 to 11 years.

According to an American Academy of Pediatrics (AAP) report drawing on data posted by the Centers for Disease Control and Prevention, as of November 30, 2022, 1.8 million children aged 6 months to 4 years have received at least 1 dose of COVID-19 vaccine, representing 10% of that population. Approximately 15.3 million children in this age group have yet to receive their first COVID-19 vaccine dose.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
© 2024 MJH Life Sciences

All rights reserved.